Table 1.
Association between RFP expression and clinicopathologic factors in patients with ovarian cancer
| Variables | Number of patients | RFP(−) | RFP(+) | P |
|---|---|---|---|---|
| Age | ||||
| <60 | 65 | 27 (41.5%) | 38 (58.5%) | 0.2840 |
| ≥60 | 27 | 8 (29.6%) | 19 (70.4%) | |
| FIGO stage | ||||
| I | 29 | 13 (44.8%) | 16 (55.2%) | 0.3632 |
| II∼IV | 63 | 22 (34.9%) | 41 (65.1%) | |
| Histological type | ||||
| Nonclear | 68 | 29 (42.6%) | 39 (57.4%) | 0.1258 |
| Clear cell | 24 | 6 (25.0%) | 18 (75.0%) | |
| Recurrence | ||||
| − | 42 | 21 (50.0%) | 21 (50.0%) | 0.0431 |
| +1 | 50 | 14 (28.0%) | 36 (72.0%) | |
| Time before recurrence (platinum-free interval) | ||||
| ≥6 months | 60 | 30 (50.0%) | 30 (50.0%) | 0.0015 |
| <6 months1 | 32 | 5 (15.6%) | 27 (84.4%) | |
RFP, RET finger protein; FIGO, International Federation of Gynecology and Obstetrics.
1
Including PD (progressive disease).